Selected Grants
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy
Clinical TrialPrincipal Investigator · Awarded by Xenon Pharmaceuticals Inc. · 2023 - 2028The overlap of speech production and verbal working memory
ResearchCo Investigator · Awarded by National Institute of Neurological Disorders and Stroke · 2023 - 2028Promoting Effective Self-Management of Chronic Pain with mHealth Neurofeedback
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2027A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Clinical TrialPrincipal Investigator · Awarded by Xenon Pharmaceuticals Inc. · 2023 - 2025MARN - Protocol 1042-SE-3004_Imaging
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2023 - 2025Epilepsy in Uganda: Clinical characterization and co-morbidities, their relation to stigma among adolescents and impact of a community-based intervention
ResearchInvestigator · Awarded by Makerere University · 2021 - 2025The role of blink reflex in predicting facial nerve outcomes following vestibular schwannoma resection
ResearchSignificant Contributor · Awarded by North American Skull Base Society · 2024 - 2025Validation of a medical-grade wearable device with interpretable artificial intelligence system for the obstructive sleep apnea-hypopnea syndrome (OSAHS) screening
Clinical TrialPrincipal Investigator · Awarded by PranaQ Pte. Ltd. · 2024 - 2025Epilepticus_EEG Coordinating Ctr.
ResearchPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2020 - 2025Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2018 - 2024Neuromodulatory Treatments for Pain Management in Complex TBI using Mobile Technology
ResearchCo Investigator · Awarded by Department of Defense · 2017 - 2022A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Clinical TrialPrincipal Investigator · Awarded by Biogen, Inc. · 2018 - 2021AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2019 - 2021A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2018 - 2020EEG Coordinating Center
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2017 - 2020Eisai Inc. Educational Program 2019
ConferencePrincipal Investigator · Awarded by Eisai, Inc. · 2019 - 2019A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110[(R)-2-amino3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in subjects with Narcolepsy or Obstructive Sleep Apnea
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2015 - 2018A Twelve-week,DoubleBlind,Placebo-controlled,Randomized, Parallel-group, Multicenter Study of Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in subjects with Narcolepsy
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2015 - 2017UCB Training Program
ConferencePrincipal Investigator · Awarded by UCB Pharma, Inc. · 2016 - 2017TwelveWeek,DoubleBlind,PlaceboControlled,Randomized,ParallelGroup,MultictrStudy of the Safety and Efficacy of JZP-110[(R)2-amino-3-phenylpropylcarbamate hydrochloride]in the treatment of ExcessiveSleepiness in Subjects with ObstructiveSleepApnea(OSA)
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2015 - 2017Combined Behavioral/Pharmacological Therapy for Insomnia
ResearchCo Investigator · Awarded by National Institutes of Health · 2001 - 2007External Relationships
- American Clinical Neurophysiology Society
- American Epilepsy Society
- Clinical Education Alliance
- Eisai Pharmaceuticals
- International Federation of Clinical Neurophysiology
- Jazz Pharmaceuticals
- Marinus Pharmaceuticals
- Merck Pharma
- PPD, Inc.
- PranaQ
- Springer Publishing Company
- UCB Pharma
- Uniqure
- Wolters Kluwer Health (publishing)
- health and wellness partners
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.